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ABSTRACT 
Background: A number of elements of the pivotal oral cladribine (CLARITY) trial are unpublished. 
Objective: To report the impact of cladribine on health-related quality of life (QoL) in people with 
relapsing multiple sclerosis (pwRMS).  
Methods:  QoL data from the phase III trial of two different doses (3.5mg/kg and 5.15mg/kg) of oral 
cladribine in pwRMS were acquired from the European Medicines Agency through Freedom of 
Information. Spearman’s rank correlation was used to analyse the relationship between baseline 
QoL scores and baseline Expanded Disability Status Scale (EDSS) scores. Responses the Euro Quality 
of Life 5 dimension (EQ5D) and Multiple Sclerosis Quality of Life 54 (MSQOL54) questionnaires were 
compared between treatment and control groups using univariate analyses of covariance. 
Results: In total n= 5,148 EQ5D responses and n= 894 MSQOL54 physical, mental-health and 
dimension scores were extracted. Baseline EQ5D indices correlated with EDSS scores. After two 
years, pwRMS taking 3.5mg/kg (p=0.001) and 5.25mg/kg (p=0.022) reported significantly improved 
EQ5D index scores compared with placebo. Positive, yet non-significant, differences were detected 
in MSQOL54 scores between cladribine and placebo. 
Conclusion: Analysis of the CLARITY dataset suggests that, over and above its established clinical 
efficacy, cladribine leads to improved QoL over 96 weeks. ClinicalTrials.gov identifier, NCT00213135 
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INTRODUCTION 
Multiple sclerosis (MS) is a major demyelinating and neurodegenerative disease resulting in the 
accumulation of disability and significant loss of Quality of Life (QoL) to the affected individual and 
their carers1,2. QoL may be retained or improved by use of effective disease modifying treatments 
(DMT) that stop or slow the accumulation of disability3. 
Cladribine is a deoxyadenosine analogue, which is phosphorylated to 2-chlorodeoxyadenosine 
triphosphate that is selectively cytotoxic for lymphocytes in humans4,5. Cladribine has activity as an 
injectable, generic agent6 or as an oral pro-drug5,7. This was particularly well demonstrated in the 
phase III “Cladribine tablets treating multiple sclerosis orally “(CLARITY) trial, where cladribine 
markedly inhibited (i) lesion accumulation as detected on magnetic resonance imaging (MRI); (ii) 
relapses and (iii) three month-sustained disability progression5,7. For a number of reasons, including 
a perceived increase in cancer risk5, and in the absence of additional trial data, the regulators 
rejected license applications prompting the manufacturer of oral cladribine to halt their programme 
for commercial development of the drug in 2011 8. Following resubmission in 2015, however, the 
Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has 
now adopted a positive opinion with licensing of oral cladribine (Mavenclad®) likely in the 3rd 
quarter 2017 (http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-
_Initial_authorisation/human/004230/WC500229786.pdf). 
Based on meeting abstracts prior to 2011, the termination of the oral cladribine programme meant 
a significant cache of data gathered during CLARITY never underwent peer- reviewed publication. 
Given the excellent efficacy of cladribine demonstrated in people with relapsing MS (pwRMS)5, as 
well as people with a first demyelinating event suggestive of MS9, and following a meta-analysis 
suggesting the cladribine-associated cancer frequency was no different to natural aging or that 
found in pivotal trials of other MS-DMT10, we saw a future in developing cladribine for people with 
MS further11,12. We therefore obtained the entire CLARITY dataset using a Freedom of Information 
(FoI) request to the EMA, which included data on health-related QoL.  
As QoL indices are particularly sensitive to fatigue, cognitive impairment, emotional changes and 
social isolation13,14, they enable a complementary assessment of the impact of DMT over and above 
clinical scales, such as the expanded disability status score (EDSS) scale, which suffers from bias, 
notably due to the dominant contribution of ambulation at scores between 3.5 and 815. 
Furthermore, QoL indices may be more sensitive to adverse effects of treatments16,17. Given the 
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efficacy of cladribine to inhibit relapsing disease5-7, we hypothesised a positive impact on QoL in 
pwRMS. 
 
MATERIALS & METHODS 
Trial Registration and data acquisition 
After the apparent termination of the commercial development of oral cladribine in 2011, and 
subsequent discussions with the UK Medicines and Healthcare products Regulatory Agency about 
approaches to develop generic cladribine, the full regulatory submission of the 96 week CLARITY 
trial (NCT00213135)5 was obtained through FoI request to the EMA (submitted May 2013; obtained 
November 2013). Whilst the original trial was undertaken following R&D approval and pwRMS 
recruited after informed consent5, no R&D approval was required to use the “public domain” 
documents used for the current analysis of anonymised datasets. Information regarding study 
design, setting, participants, eligibility, variables, randomization, blinding, study size, bias reduction, 
flow diagrams of participants and the CONSORT and STROBE reporting guidelines can be obtained 
from the original trial publication5. 
 
The dataset from the EMA was provided in portable document format (pdf). Files containing 
relevant data were identified and converted into Microsoft Excel spreadsheets using a pdf parser 
developed on a Python 2.7 platform at the MidPlus computational facilities at Queen Mary 
University of London (code available on request). The converted data was validated by comparing 
sample records between pdf and spreadsheet versions of the files. Scores listed as “unscheduled” or 
“99999” were excluded from analysis.  
 
Trial Design 
The full details of the trials have been reported previously5. Briefly, 1326 pwRMS were randomized 
1:1:1 (n=1184 completed the 96 week study) to receive either placebo (n=437; n=380 completed), 
or one of two doses of oral cladribine pro-drug. Patients were given tablets containing either 
10mg/day (60-69.9kg body weight) or 20mg/day (70-79kg body weight) cladribine administered for 
4-5 days in weeks 0 and 5 (year 1) and weeks 48 and 52 (year 2) to result in a total cumulative dose 
of 3.5mg/kg (n=433. n=398 completed). Those randomized to the 5.25mg/kg arm were given 
additional doses in weeks 9 and 13 (n=456; n=406 completed)5.  Clinical efficacy was comparable for 
both doses of cladribine5,7. QoL scores were collected at baseline and at weeks 24, 48, 72 and 96. 
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Quality of Life indices 
The regulatory submission included the EuroQol five dimension three level (EQD5-3L)18 and the 
Multiple Sclerosis Quality of Life-54 (MSQOL-54)1,19 questionnaires.  
The EQ5D-3L, a self-completed questionnaire, addresses five distinct dimensions, (i) mobility, (ii) 
self-care, (iii) usual activities, (iv) pain or discomfort and (v) anxiety, where participants had a choice 
of three responses per dimension: no problems, moderate problems or severe problems18. A 
scoring algorithm was implemented to convert responses into a summary index, known as the EQ5D 
index18, where 1 represents the best QoL. Values below 0 were not excluded. Values marked on a 
self-rating Visual Analogue Scale (VAS), known as EQ5D-VAS, were also collected.  EQ5D-VAS scores 
on a scale 0-100, where 0 represented the worst QoL.  The EQ5D was collected at baseline and at 
weeks 24, 48, 72 and 96.   
The MSQOL-54 is a fifty-four item questionnaire that measures twelve domains: physical function, 
role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health 
perceptions, social function, cognitive function, health distress, overall QoL, and sexual function1. 
Subscale and summary scores were calculated as described previously19. For each domain, relevant 
item scores were totalled and then divided by the number of completed responses. This gave a 
score for each of the twelve domains. Physical-health (PHS) and mental-health (MHS) component 
scores were calculated from weighting relevant domains and summing the resultant products.  Male 
and female sexual function domain scores were added together to provide a single physical 
component summary score. The MSQOL-54 scores ranged between 0 and 100 where 100 
represented the highest quality of life. Changes from baseline scores were calculated for each time 
point. The MSQOL-54 was collected at baseline and at weeks 24, 48, 72, 96.   
Statistical Analysis 
The relationship between baseline QoL scores and baseline EDSS was assessed using Spearman’s 
rank correlation. Univariate analyses of covariance (ANCOVA) tests, adjusted for baseline score, age 
at baseline, centre, ethnic group, and gender were conducted to compare mean QoL scores at 
baseline, and at weeks 24, 48, 72 and 96. This method was in line with EMA guidelines20 and similar 
to those used in previous QoL studies21, 22.  The impact of relapses on QoL was also assessed using 
ANCOVA analysis, comparing pwRMS who had a relapse, requiring steroid use as a reflection of the 
severity, between treatment and placebo-control groups. Relapses listed as “unscheduled” were 
not included as relapses up to week 48, because it could not be safely assumed that these relapses 
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occurred during this time. However, all relapses including those listed as “unscheduled” were 
included as relapses up to week 96 and were totalled for each treatment arm. To investigate 
whether changes in EQ5D index were independent of relapse reduction, two linear regression 
models were compared. The first model set high dose, low dose groups and their baseline index 
scores as predictors for changes in EQ5D index at week 96. The second model also adjusted for 
whether participants relapsed at any point during the trial (a binary variable).   
Changes in EQ5D were examined using the index of “minimal clinically important difference” 
(MCID)23, defined as the smallest QoL change that pwRMS considered important. This is because 
changes greater than the MCID are more likely to translate to real-world patient benefit24. 
Previously, based on data from the North American Research Committee on Multiple Sclerosis 
(NARCOMS) registry the EQ5D-3L MCID was between 0.050 and 0.08423The likelihood that a patient 
experienced a QoL change greater than the MCID, set at 0.08, was assessed using a logistic 
regression model. The covariates were high, low dose groups and index scores at baseline. The 
dependent variable was whether or not individuals achieved a MCID in change EQ5D index. The 
sample population came from the entire trial period (from week 24 to week 96). All statistical 
analysis was performed using SPSS version 23. No imputation was made for missing data.  
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RESULTS 
Analysis of respondent demography showed that the age and the gender ratio in the respondent 
sample matched the overall demography of the CLARITY trial3, with no significant imbalances 
between treatment groups (Supplementary data. Table S1).  At baseline pwRMS with higher EDSS 
scores had a lower EQ5D index (rs= -0.472, n= 430, p< 0.001) and EQ5D VAS score (rs=-0.442, n= 434, 
p< 0.001).  
Effect of cladribine on EQ5D Index 
At baseline, differences in EQ5D-index and EQ5D-VAS scores between groups were not statistically 
significant. Participants receiving placebo experienced worsening in mean QoL over the duration of 
the trial reaching the lowest point by week 96 (Figure 1). In weeks 24, 72 and 96 the mean index 
change between groups was significantly different. In week 24, (F[2, 950] = 5.514, p=0.004), 
participants treated with the low dose of cladribine had significantly higher index scores compared 
with placebo, likewise for the high dose of cladribine, (p= 0.014 for low-dose, p= 0.003 for high-
dose).  In week 72, only the low dose cladribine group had significantly higher scores compared with 
placebo (F[2, 899] = 4.340, p=0.013), p= 0.003 for low dose). Finally in week 96, (F[2, 945] = 5.639, 
p=0.004), participants treated with either dose of cladribine had significantly higher EQ5D index 
scores compared to placebo (planned contrast analysis; p= 0.001 for low-dose, p= 0.022 for high-
dose).  
Impact of cladribine on EQ5D VAS 
Whilst the 3.5mg/kg cladribine group experienced consistent improvement in mean VAS scores 
throughout the trial, the placebo group reported worse than baseline VAS scores throughout the 
trial. However, none of these differences were statistically significant at any time point over the 
duration of the trial (Table S1). 
Impact of cladribine on EQ5D index after relapse 
An ANCOVA adjusted for: age, gender, centre, baseline score, ethnicity and treatment group was 
used to assess the impact of relapses on the mean observed EQ5D index and VAS scores. This 
analysis was performed on scores reported by pwRMS at the end of weeks 48 and 96. The analysis 
showed that EQ5D-VAS scores in pwRMS who had at least one relapse up to week 48, (M = 0.60, SD 
= 0.21) was significantly lower than in patients who did not relapse (M = 0.71, SD = 0.21; F(1, 923) = 
19.178, p < 0.001). Similarly, pwMS who relapsed by week 48 of the trial (M = 0.63, SD = 0.26) had 
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significantly lower EQ5D index scores compared with pwMS who did not relapse (M = 0.73, SD = 
0.22; F(1, 913) = 13.440, p < 0.001).Similarly, participants who relapsed by week 96 also had a 
significantly lower EQ5D Index compared to non-relapsed participants (0.60 vs. 0.73; F(1, 945) = 
29.052, p < 0.001). This effect was also evident for EQ5D-VAS scores up to week 96, (0.61 vs. 0.71; 
F[1, 956] = 29.644, p  < 0.001), suggesting that relapses had a detrimental effect on QoL.  
ANCOVA adjusted for: age, gender, centre, baseline score and ethnicity was also used to assess the 
impact of cladribine on QoL scores in pwRMS experiencing a relapse. There was no statistically 
significant difference in EQ5D Index between groups within those who relapsed at week 48 or week 
96. However, there were differences in the EQ5D VAS(F[2, 101] = 3.124, p  = 0.048). The VAS score 
was significantly greater (better QoL) in relapsed placebo patients (M = 0.62, SD = 0.22) compared 
with relapsed low dose patients (M = 0.52, SD = 0.20; planned contrast analysis p = 0.039). Thus, if 
they had a relapse, pwRMS treated with cladribine had no better QoL compared to pwRMS on 
placebo. 
Two linear regression models were compared to explore the influence of relapse reduction on 
changes in QoL further. The first model, which set doses and baseline scores as independent 
variables, showed that both high (p=0.028) and low dose (p=0.001) groups were significantly higher 
than placebo at Week 96. However, when relapses up to week 96 were added as another 
independent variable in a second regression model, the high dose improvement was reduced and 
no longer significant (p=0.161). The low dose effect remained significant (p=0.016) even after 
adjustment for relapses. 
Impact of cladribine on EQ5D dimensions 
The proportion of pwRMS reporting at least one point increase at week 96, which indicated 
worsening of their EQ5D dimensions was compared between treatment and control groups (Table 
1). It was found that only the self-care dimension reached significance (P<0.01) for both of the 
cladribine treatment groups (Table 1). Furthermore a larger proportion of pwRMS on placebo 
worsened in mobility and anxiety dimensions compared with people treated with cladribine (Chi 
square; mobility: 𝜒2 = 7.911, p= 0.019 [2d.f. n= 964]; self-care: 𝜒2 = 7.104, p= 0.029 [2d.f. n= 964], 
anxiety: 𝜒2 = 6.389, p = 0.041 [2d.f. n=964]). 
Impact of cladribine on pwRMS reporting a MCID in EQ5D 
Proportions of pwRMS achieving MCID in their EQ5D index score change at each time point are 
detailed in table 2. Our logistic model (𝜒2 = 368.7 p< 0.001 [3d.f. n= 4076]) showed that Individuals 
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on a low dose had an odds ratio of 1.26 (p=0.019) compared to placebo. Those on high dose had an 
odds ratio of 1.06 (not statistically significant). 
Impact of cladribine on MSQOL54 scores 
The number of MSQOL-54 responses was small (n=45-73). Baseline MSQOL54 physical and mental 
health component scores between groups were not significantly different (Supplementary data. 
Table S2). Univariate ANCOVA analyses adjusted for baseline score, age gender, centre and ethnicity 
were conducted at each time point to assess the impact of oral cladribine on MSQOL-54 physical 
and mental health component scores failed to show significant improvements compared to placebo 
(Supplementary data. Table S2) at any point. 
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DISCUSSION 
Following refusal by the EMA to license oral cladribine in 2011, the drug was withdrawn from 
markets, where it had been licensed (Russia, Australia), and ongoing trials were terminated8,9.  
However, the high efficacy and modest adverse effect profile of cladribine in pwRMS5,7,10 led us to 
seek information that could help inform on the merits of preparations other than the one used in 
CLARITY. Parenteral cladribine, which is available as a generic drug for treatment of people with 
hairy cell leukaemia, may have benefits for personalized dosing due to its consistent bioavailability 
of 100% compared to the oral route with a mean of 42% bioavailability25 prompting a study 
exploring combination of the acid sensitive oral cladribine pro-drug with the proton pump inhibitor 
pantoprazole (NCT00938366; the study has yet to be reported). However, a successful FoI request 
to the EMA for documentation placed in the public domain in 2009 enabled us to independently 
analyse the trial data. Here, we present class II evidence that cladribine has QoL benefits in addition 
to the clinical benefits previously reported5,7,9.   
 
The key result of this analysis is that cladribine, at both doses used in CLARITY, 3.5mg/kg and 
5.25mg/kg orally5, significantly improved QoL as measured using the widely accepted EQ5D index. 
The benefits in EQ5D for pwRMS treated with both doses was particularly significant for self-care, 
although influences on mobility could be detected and may be related to the clinical efficacy of 
cladribine in reducing relapses and delaying progression5,7. It is plausible these clinical effects also 
translate into reduced anxiety. 
 
The data collected during CLARITY are in line with previous studies suggesting that relapses have a 
significant impact on QoL16,26.  The implication from linear regression is that the beneficial effect on 
QoL using the higher dose was mediated by the relapse-reducing effect of cladribine, whereas at 
the lower dose cladribine may also lead to improved QoL independent of its relapse-reducing effect. 
Given there was no difference in efficacy between the two doses during CLARITY, we hypothesize 
the lower incidence of adverse effects in the low dose group as the potential cause for the “relapse-
independent” QoL benefit on the lower dose.  
 
The magnitude of QoL benefits was sufficiently robust to reflect in the MCID, suggesting improved 
QoL was noticeable at the level of the individual patient.  Whilst the EQ5D-VAS score change was 
consistent with the EQ5D, differences between groups were small and did not reach statistical 
significance. The reason for this may be the lower sensitivity of this QoL index, where there may be 
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issues with completion and coding implementation and where health improvements are less likely 
to be reported27. Furthermore, no difference was detected using the MSQOL-54, likely due to the 
small number of respondents not providing a statistically meaningful sample. 
 
Given only few fully-blinded head-to-head studies have been undertaken so far, it is difficult to 
compare QoL indices between different interventions for pwRMS directly. Not all DMT have had an 
impact on QoL indices28, 29, however improvements have been detected with treatments including 
dimethyl fumarate21, natalizumab22 and alemtuzumab30. Recently, alemtuzumab was shown to 
improve the EQ5D index and the EQ5D-VAS, and physical and mental health components of short 
form-36 questionaire30. It should be kept in mind, however, that pwRMS receiving alemtuzumab 
were unblinded to treatment allocation due to the infusions and infusion related reactions31, which 
precludes accounting for placebo effects.  
 
On the basis of the data collected during CLARITY5,7, cladribine was highly effective in controlling 
MRI lesion accrual, relapses, and deterioration of disease-related disability5,7, further corroborated 
by reduction in brain atrophy32. As a rule, high-efficacy DMT are currently associated with a higher 
frequency of treatment-related adverse effects, such as opportunistic infections, notably 
progressive multifocal leukoencephalopathy, and the development of secondary 
autoimmunities33,34, which do not appear to be a feature of cladribine induction therapy5,7,9 
 
Limitations 
Reviewing the protocol and amendments of CLARITY between 2005 and 2008 suggests measuring 
QoL was not considered as important as in more recent trials. The EQ5D was the only index included 
in the first version (January 2005) of the CLARITY protocol, whilst MSQOL-54, 36-Item Short Form 
Survey (data not included due to small number of responses) and an analysis plan were only added 
later in 2005 and 2006. As a result, the EQ5D remained the only index for which the number of 
responses enabled robust analysis. Whilst the number of MSQOL-54 responses was limited, making 
it less straightforward to interpret how cladribine affected specific domains, the EQ5D dimension 
results indicate that cladribine broadly improved symptoms associated with self-care. The original 
analysis plan of CLARITY included comparative analysis between the two cladribine groups and the 
placebo group using Hochberg’s step-up multiple comparison. However, we used ANCOVA 
methodology and planned contrast analysis, which are not significantly different. 
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In conclusion, we independently analysed QoL data collected during the largest ever trial of 
cladribine versus placebo in pwRMS.  Over and above the established efficacy of cladribine on 
clinical outcomes5,7, the treatment led to significant improvement in QoL. These results further 
underpin the potential of cladribine as a DMT for pwRMS, be it as a drug licensed for MS, as is 
currently being sought once again in Europe35, or using an off-label preparation6,12. 
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Table 1: Mean change in EQ5D dimensions for cladribine and placebo groups 
Treatment Mobility Self-Care Activity Pain Anxiety 
Placebo 0.04± 0.46 0.15 ± 0.50 0.03 ± 0.60 0.00 ± 0.59 0.08 ± 0.66 
3.5mg/kg cladribine 
 
-0.05 ± 0.41 
   N.S. P=0.013 
0.05 ± 0.43 
P=0.008 
-0.02 ± 0.53 
N.S. P>0.05. 
-0.05 ± 0.59 
N.S. P>0.05. 
-0.03 ± 0.59 
N.S. P=0.028 
5.25mg/kg cladribine 
 
-0.02 ± 0.45 
N.S. P>0.05 
0.05 ± 0.45 
P=0.003 
0.04 ± 0.60 
N.S.P>0.05. 
0.00 ± 0.62 
N.S. P>0.05. 
-0.02 ± 0.62 
N.S. P=0.029 
 
EQ5D was established at baseline and 96 weeks following treatment with either 3.5mg/kg or 
5.25mg/kg. The results represent the mean ± standard deviation.  Differences between treatment 
and placebo was assessed using ANCOVA. P<0.01 was considered significant for multiple 
comparisons involving 5 outcomes. 
 
Table 2: Counts and proportions of participants achieving MCID for each treatment arm  
Timepoint Group 
Number within MCID 
≥ 0.08 (%) 
Week 24 
 
Cladribine 3.5 77 (36.8) 
Cladribine 5.25 70 (33.5) 
Placebo 62 (29.7) 
Week 48 
 
Cladribine 3.5 98 (39.5) 
Cladribine 5.25 77 (31.0) 
Placebo 73 (29.4) 
Week 72 
 
Cladribine 3.5 75 (33.6) 
Cladribine 5.25 82 (36.8) 
Placebo 66 (29.6) 
Week 96 
 
Cladribine 3.5 84 (35.7) 
Cladribine 5.25 87 (37.0) 
Placebo 64 (27.2) 
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Figure 1  The impact of cladribine on EQ5D  
People with relapsing MS were treated with either placebo (circle; n= 281-310) or 3.5mg/kg 
cladribine (diamond; n= 306-319) on weeks 0, 5, 48 and 52 or treated with 5.25mg/kg (hexagon; n= 
320-329) by receiving additional oral doses in weeks 9 and 13. The results represent the mean ± 
standard error of the mean. *p<0.05, **p<0.01 compared to placebo. Inverse triangles indicate time 
points of drug administration. 
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SUPPLEMENTARY DATA 
Table S1: Baseline EQ5D respondents at baseline and in response to treatment 
Variable Placebo Cladribine 3.5mg/kg Cladribine 5.25mg/kg 
EQ5D respondents at Baseline 
Mean Age (Range) Year 39.1 ± 9.7 (18-62) 38.2 ± 10.2 (18-65) 39.8 ± 9.6 (18-65) 
Female Responses* (%) 1092 (65.9) 1200 (67.2) 1189 (69.8) 
Median (Range) EDSS 3 (0-6) 3 (0-6) 3 (0-6) 
EQ5D respondents at Baseline 
N (pwRMS) 349 353 370 
Mean EQ5D  Index (Range) 0.72  ±  0.19 (-0.04-1.00) 0.72 ± 0.20 (-0.02-1.00) 0.71 ±  0.21(-0.18-1.00) 
Mean EQ5D VAS (Range) 68.9  ±  21.1 (0-100) 70.22 ± 19.1 (0-100) 69.1 ±  19.3 (0-100) 
EQ5D respondents at  24 weeks 
N (pwRMS) 341 336 353 
Mean EQ5D  Index (Range) 0.68  ±  0.23 (-0.17-1.00) 0.72 ± 0.20 (-0.02-1.00) 0.71 ±  0.20(-0.08-1.00) 
Mean EQ5D VAS (Range) 66.8  ±  21.7 (0-100) 70.7 ± 22.2 (18-100) 69.3 ±  19.1 (0-100) 
EQ5D respondents at  48 weeks 
N (pwRMS) 318 338 354 
Mean EQ5D  Index (Range) 0.70  ±  0.22 (-0.24-1.00) 0.72 ± 0.22 (-0.18-1.00)  0.70 ±  0.23 (-0.18-1.00) 
Mean EQ5D VAS (Range)  67.7  ± 20.6 (0-100) 70.7 ± 18.1 (0-100) 68.0 ± 21.3 (0-100) 
EQ5D respondents at  72 weeks 
N (pwRMS) 312 332 350 
Mean EQ5D  Index (Range) 0.67  ±  0.26 (-0.43-1.00) 0.74 ± 0.20 (-0.18-1.00)  0.69  ±  0.25 (-0.26-1.00) 
Mean EQ5D VAS (Range)  66.8  ± 21.2 (0-100) 71.5 ± 17.9 (0-100) 68.3 ± 20.8 (0-100) 
EQ5D respondents at 96 weeks 
N (pwRMS) 338 345 359 
Mean EQ5D  Index (Range) 0.66  ±  0.26 (-0.33-1.00) 0.73 ± 0.22 (-0.02-1.00)  0.70 ±  0.23 (-0.17-1.00) 
Mean EQ5D VAS (Range)  66.3  ± 22.6 (0-100) 71.9 ± 19.4 (0-100) 68.3 ± 20.7 (0-100) 
 
Demographics and clinical characteristics of baseline EQ5D respondents in placebo, low dose and high dose 
cladribine groups. *Number of responses from all time points. Results represent mean ± standard deviation. 
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Table S2: Baseline MSQOL-54 respondents at baseline and in response to treatment 
 
Variable Placebo Cladribine 3.5mg/kg Cladribine 5.25mg/kg 
MSQOL-54 respondents at Baseline 
Mean Age (Range) Year 38.3 ± 8.9 (19-58) 38.9 ± 10.1 (24-65) 42.0 ± 9.6 (19-65) 
Female Responses* (%) 196 (68.5%) 204 (73.6%) 259 (78.2%) 
Median (Range) EDSS 2.5 (0-5) 2.5 (1-6) 2.5 (1-6) 
MSQOL-54 respondents at Baseline 
N (pwMS) 51 50 57 
Mean PHS (Range)  0 week 54.0  ±  18.0 (16-92) 51.4 ± 17.1 (19-90) 54.5 ±  16.8 (24-85) 
Mean MHS (Range) 0 week 70.0  ±  19.0 (23-96) 65.6 ± 19.3 (23-93) 69.4 ±  22.4 (12-97) 
MSQOL-54 respondents at 24 weeks 
N (pwRMS) 55 45 63 
Mean PHS (Range)  55.2  ±  16.7 (17-90) 52.6  ±  17.0 (35-92) 56.4  ±  18.9 ( 8-89) 
Mean MHS (Range)  71.0  ±  18.4 (18-98) 69.2  ± 18.3 (33-92) 71.0  ±  22.4 ( 7-97) 
MSQOL-54 respondents at 48 weeks 
N (pwRMS) 65 65 72 
Mean PHS (Range)  52.2  ±  17.2 (17-91) 56.1  ±  21.8 (12-95) 54.2  ±  18.4 (13-96) 
Mean MHS (Range)  71.0  ±  18.4 (18-98) 70.5  ± 20.5 (25-96) 68.8  ±  23.1 (11-97) 
MSQOL-54 respondents at 72weeks 
N (pwRMS) 55 57 65 
Mean PHS (Range)  54.6 ±  18.7 (20-91) 53.0  ±  20.6 (18-91) 52.7  ±  19.5 (10-89) 
Mean MHS (Range)  68.3  ±  23.2 (11-97) 66.7  ±  20.5 (29-95) 68.8  ±  23.4 (10-96) 
MSQOL-54 respondents at 96weeks 
N (pwRMS) 65 65 72 
Mean PHS (Range)  52.2  ±  17.2 (17-91) 56.0  ±  20.7 (18-94) 56.7  ±  19.1 (12-90) 
Mean MHS (Range)  68.5  ±  20.9 (14-99) 71.0  ±  21.1 (21-96) 71.4  ±  21.1 (24-95) 
 
Demographics and clinical characteristics of baseline MSQOL-54 respondents in placebo, low dose and high 
dose cladribine groups. *Number of responses from all time points. Results represent mean ± standard 
deviation. 
 
 
 
 
